Pharma Focus Asia

Jacobio Announces Clinical Collaboration to Evaluate CD73 Monoclonal Antibody JAB-BX102

Thursday, March 23, 2023

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer.

The clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA for the treatment of advanced solid tumours. Under the terms of the agreement, Merck & Co will provide KEYTRUDA®.

The CD73 monoclonal antibody is Jacobio’s first large molecule project to enter the clinic. CD73 is an important target in the tumour immune pathway. The combination of CD73 and anti-PD-1, an inhibitor on the same tumour immune pathway, can potentially relieve immunosuppression in the tumour microenvironment, stimulate the proliferation and activation of killer immune cells, and enhance tumour immunity.

JAB-BX102 is a humanised CD73 monoclonal antibody developed by Jacobio that was granted approvals for clinical trials in the U.S. and China in October 2021 and March 2022. Jacobio is currently initiating a Phase I/IIa, multi-centre, open study of the safety, tolerability, pharmacokinetics and preliminary anti-tumour efficacy of JAB-BX102 alone and in combination with pablizumab to treat advanced solid tumours in China and the U.S. Current published clinical data show that CD73 in combination with PD-(L)1 significantly prolongs survival of patients with non-small cell lung cancer.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference